Future of Johnson & Johnson | Quantumrun

Future of Johnson & Johnson

Johnson & Johnson is a US pharmaceutical, consumer packaged goods, and medical devices producing company established in 1886. Johnson & Johnson is headquartered in New Brunswick, New Jersey. Its consumer division is in Skillman, New Jersey.

Home Country: 
United States
Industry: 
Pharmaceuticals
Industry vulnerability to disruption: 

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations. However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.
*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.
*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.
*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.
*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.

Total patents held: 
2 523
Number of patents field last year: 
73
Ranking List: 
6
Ranking List: 
2017 Quantumrun Global 1000
4
Ranking List: 
2017 Quantumrun US 500
Ranking List: 
2017 Quantumrun Silicon Valley 100
Market Revenue Country: 
Market country 
United States
Revenue from country 
0.53
Market country 
Europe
Revenue from country 
0.22
Prod/Serv name revenue: 
Prod/Serv name: 
Pharmaceutical
Prod/Serv revenue: 
33464000000
Prod/Serv name: 
Medical devices
Prod/Serv revenue: 
25119000000
Prod/Serv name: 
Consumer
Prod/Serv revenue: 
13307000000
Founded: 
1886
Global brand rank: 
79
Company Name: 
Johnson & Johnson
Sector: 
Revenue: 
71890000000
3y average revenue: 
72098333333
Operating expenses: 
52087000000
3y average expenses: 
52244333333
Company profile data note: 
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.
Global employee count: 
126400
Funds in reserve: 
18972000000
Investment into R&D: 
9095000000
create term: 
#6 | 2017 Quantumrun Global 1000
#4 | 2017 Quantumrun US 500

Johnson & Johnson is a US pharmaceutical, consumer packaged goods, and medical devices producing company established in 1886. Johnson & Johnson is headquartered in New Brunswick, New Jersey. Its consumer division is in Skillman, New Jersey.

Home country:
United States
Sector:
Health Care
Industry:
Pharmaceuticals
Founded:
1886
Global employee count:
126,400

Financial Health

Revenue
$71,890,000,000 USD
3y average revenue
$72,098,333,333 USD
Operating expenses
$52,087,000,000 USD
3y average expenses
$52,244,333,333 USD
Funds in reserve
$18,972,000,000 USD
#1 Market country
United States
% of revenue from country #1
0.53%
#2 Market country
Europe
% of revenue from country #2
0.22%

Asset Performance

#1 Product/Service/Dept. name
Pharmaceutical
#1 Product/Service revenue
$33,464,000,000 USD
#2 Product/Service/Dept. name
Medical devices
#2 Product/Service revenue
$25,119,000,000 USD
#3 Product/Service/Dept. name
Consumer
#3 Product/Service revenue
$13,307,000,000 USD

Innovation assets and Pipeline

Global brand rank
79
Investment into R&D
$9,095,000,000 USD
Total patents held
2,523
Number of patents field last year
73
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.

Disruption Vulnerability

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations. However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.
*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.
*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.
*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.
*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.